SUBSCRIBE
SUBSCRIBE
News   Policy

Regeneron Pharmaceuticals, Inc. Says FDA Extends Priority Review of CAPS Treatment

November 2, 2007 | 
1 min read
Nov 1 (Reuters) - Regeneron Pharmaceuticals Inc (REGN.O: Quote, Profile, Research) said U.S. regulators have extended the date for taking action on a priority review of the company's treatment for a rare chronic inflammatory disease known as CAPS.
Regulatory
Regeneron Pharmaceuticals, Inc.
MORE ON THIS TOPIC
A scientist with pill bottles in front of FDA headquarters
FDA
7 FDA decisions to watch for in Q3
July 2, 2026
 · 
7 min read
 · 
Tristan Manalac
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Approvals
Vertex’s Casgevy becomes first approved gene therapy for young kids with rare blood disorders
July 2, 2026
 · 
2 min read
 · 
Tristan Manalac
Killer Whale, orcinus orca, Adult Leaping, Canada
Approvals
Orca opens up Treg cell therapy with FDA nod for allogeneic blood cancer treatment
July 1, 2026
 · 
2 min read
 · 
Heather McKenzie
Approved and confirmed document file with check mark icon flat cartoon, concept of agreement or contract symbol with checkmark, accepted or certified license paper form pictogram isolated image
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
 · 
2 min read
 · 
Nick Paul Taylor